Preliminary results from a subset of patients (pts) with advanced head and neck squamous carcinoma (HNSCC) in a dose-escalation and doseexpansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)

Files in this item

Find Full text

This item appears in the following Collection(s)

Share

Search ResearchSpace


Browse

Statistics